scispace - formally typeset
S

Shuichi Fujioka

Researcher at Jikei University School of Medicine

Publications -  73
Citations -  2460

Shuichi Fujioka is an academic researcher from Jikei University School of Medicine. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 19, co-authored 65 publications receiving 2142 citations. Previous affiliations of Shuichi Fujioka include University of Texas Health Science Center at Houston & University of Texas MD Anderson Cancer Center.

Papers
More filters
Journal ArticleDOI

NF-κB and AP-1 Connection: Mechanism of NF-κB-Dependent Regulation of AP-1 Activity

TL;DR: A distinct and essential role of NF-κB is revealed in participating in the regulation of elk-1, c-fos, and VEGF expression, and it is shown that elk -1, a member of TCFs, is one of the NF-σκB downstream target genes.
Journal ArticleDOI

Tokyo Guidelines 2018 surgical management of acute cholecystitis: safe steps in laparoscopic cholecystectomy for acute cholecystitis (with videos)

TL;DR: It is absolutely necessary to avoid any increase in bile duct injury (BDI), particularly vasculo‐biliary injury (VBI), which is known to occur at a certain rate in LC.
Journal Article

Function of Nuclear Factor κB in Pancreatic Cancer Metastasis

TL;DR: In this article, the role of NFκB in the development of pancreatic adenocarcinoma was investigated, and it was shown that the activation of the transcription factor is activated constitutively in human pancreatic cancer cells.

Function of Nuclear Factor B in Pancreatic Cancer Metastasis 1

TL;DR: It is shown that inhibiting constitutive NFκB activity by expressing IκBαM suppresses liver metastasis, but not tumorigenesis, from the metastatic human pancreatic tumor cell line AsPc-1 in an orthotopic nude mouse model, and suggest that theNFκB signaling pathway is a potential target for anticancer agents.
Journal ArticleDOI

The function of multiple IκB:NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis

TL;DR: The inhibition of constitutive NF-κB activity, either by ectopic expression of IκBαM or by treating the cells with a proteasome inhibitor PS-341 which blocks intracellular degradation of IσBα proteins, downregulates the expression of bcl-xl, demonstrating the important function of various NF-kkB/IκB complexes in regulating anti-apoptotic genes in response to apoptotic stimuli.